Idacio

Adalimumab, the active ingredient in Idacio, is a TNF‑alpha inhibitor presented as a solution for injection for subcutaneous use. It is indicated for adult patients with inflammatory autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

GNH USA supplies Idacio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idacio (adalimumab) targets the TNF‑alpha pathway, a key driver of inflammation in several autoimmune disorders. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriatic arthritis: alleviates skin and joint symptoms and improves functional ability. - Ankylosing spondylitis: diminishes spinal inflammation and enhances mobility. - Crohn’s disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: promotes mucosal healing and reduces disease activity. - Plaque psoriasis: clears skin lesions and decreases scaling.

Adalimumab may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site reactions: redness, swelling or pain at the injection site. - Upper respiratory infections: mild cold‑like symptoms. - Headache: transient and usually mild. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Serious infections: including tuberculosis, bacterial sepsis or opportunistic fungal infections. - Malignancies: increased risk of lymphoma and other cancers. - Heart failure: worsening of existing cardiac insufficiency or new onset heart failure.

Before initiating Idacio, several safety considerations should be reviewed. - Screen for latent TB: perform tuberculin skin test or interferon‑γ release assay prior to therapy. - Monitor for infections: advise patients to report fever, cough or unusual symptoms promptly. - Assess cardiac status: avoid use in patients with moderate to severe heart failure. - Avoid live vaccines: do not administer live attenuated vaccines during treatment. - Use caution in demyelinating disease: discontinue if new neurologic symptoms appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use of other biologic immunosuppressants (e.g., abatacept, rituximab): increased risk of severe infection. - Live bacterial or viral vaccines: may cause uncontrolled infection. - Combination with anakinra or other anti‑IL‑1 agents: heightened immunosuppression.

Moderate Interactions (Monitor Closely): - Methotrexate or azathioprine: may enhance immunosuppressive effect; monitor blood counts and liver function. - Corticosteroids: may increase infection risk; adjust monitoring frequency.